We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer.
- Authors
Ono, Akira; Naito, Tateaki; Murakami, Haruyasu; Takahashi, Toshiaki; Nakamura, Yukiko; Tsuya, Asuka; Kaira, Kyoichi; Igawa, Satoshi; Shukuya, Takehiro; Tamiya, Akihiro; Kaira, Rieko; Endo, Masahiro; Yamamoto, Nobuyuki
- Abstract
No investigation of S-1 monotherapy in previously treated advanced non-small-cell lung cancer (NSCLC) patients has yet been reported. We conducted a retrospective study to evaluate the efficacy and tolerability of S-1 in patients with failure of second- or further-line chemotherapy. The records of NSCLC patients who had received S-1 monotherapy between January 2005 and November 2006 with the following eligibility criteria were reviewed: previously treated with at least two regimens including platinum and docetaxel in the case of nonadenocarcinoma patients, and including platinum, docetaxel and epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) in the case of adenocarcinoma patients. S-1 was administered for 28 consecutive days, followed by a 14-day drug-free period (42 days in one course). The drug was administered in two divided doses daily at 80 mg/day for patients with a body surface area <1.25 m2, 100 mg/day for those with a body surface area of 1.25–1.5 m2, and 120 mg/day for those with a body surface area ≥1.5 m2. Thirty-five patients were registered. The median number of courses administered per patient was 2 (range 1–9). The toxicity profile was mild, and grade 3 or more severe toxicity was rare. The overall response and disease control rates were 5.7% and 40%, respectively. The median survival time was 208 days. S-1 exhibits modest activity and acceptable toxicity when used as a third or subsequent line of chemotherapy in patients with advanced NSCLC.
- Subjects
LUNG cancer; CANCER patients; DRUG therapy; DOCETAXEL; EPIDERMAL growth factor
- Publication
International Journal of Clinical Oncology, 2010, Vol 15, Issue 2, p161
- ISSN
1341-9625
- Publication type
Article
- DOI
10.1007/s10147-010-0034-0